PPD skin test enhances bacillus Calmette-Guerin Tx in bladder CA

May 16, 2018

(HealthDay)—For patients with non-muscle invasive bladder cancer, undergoing the purified protein derivative skin test prior to bacillus Calmette-Guérin therapy may have therapeutic impact, according to a study published in the June issue of The Journal of Urology.

Naoya Niwa, M.D., from the Keio University School of Medicine in Tokyo, and colleagues treated 498 patients with non-muscle with adjuvant bacillus Calmette-Guérin; 320 of the patients underwent the purified derivative skin test one to two weeks before therapy.

The researchers found that the mean ± standard deviation five-year recurrence-free survival rate was 66.6 ± 2.8 percent and 59.1 ± 4.1 percent for patients who did and did not undergo the purified protein derivative skin test, respectively (P = 0.048). There were no significant differences between the groups in progression-free survival. Significant independent associations with tumor recurrence were seen for a history of recurrence, multiple tumors, the bacillus Calmette-Guérin Connaught strain, seven or more bacillus Calmette-Guérin instillations, and undergoing the purified protein derivative skin test. Overall, 24.1 and 15.2 percent of who did and did not undergo the test, respectively, had major bacillus Calmette-Guérin-related side effects (P = 0.02).

"Combination therapy with bacillus Calmette-Guérin using the purified protein derivative skin may improve the oncologic outcomes of that therapy," the authors write.

Explore further: Bacillus Calmette-Guerin vaccine may reduce atopic dermatitis

More information: Abstract/Full Text

Related Stories

Bacillus Calmette-Guerin vaccine may reduce atopic dermatitis

September 25, 2017
(HealthDay)—Bacillus Calmette-Guérin (BCG) vaccination within seven days of birth may reduce the risk of allergic diseases, including atopic dermatitis, according to a study published online Sept. 20 in Allergy.

Phase III research represents potential shift in standard of care for bladder cancer

April 2, 2012
Use of the Connaught strain of bacillus Calmette-Guérin, an adjuvant immunotherapy used in the treatment of non-muscle-invasive bladder cancer, significantly reduced cancer recurrence compared with the Tice strain of ...

Sonic Hedgehog variations linked to recurrence, survival and response to therapy of bladder cancer

December 9, 2009
Genetic variations in the Sonic Hedgehog pathway increase the likelihood of recurrence, reduce survival time and limit response to therapy for people with non-muscle invasive bladder cancer, scientists from The University ...

Heating chemotherapy drugs may improve bladder cancer treatment

May 17, 2016
Scientists have found that heating the chemotherapy drug mitomycin-C prior to using it for treating bladder cancer may radically improve its efficacy. The findings, published in the International Journal of Hyperthermia, ...

Clinical trials of VPM1002 as a tuberculosis vaccine in newborns

March 24, 2015
The only tuberculosis vaccine currently approved, the Bacillus Calmette-Guérin (BCG) vaccine, protects children from the most severe forms of the disease in most cases but does not provide protection against the most common ...

Clinical trial could lead to new bladder cancer drug

November 24, 2015
A bladder cancer drug tested in a University of Hawai'i Cancer Center clinical trial is getting closer to Food and Drug Administration (FDA) approval. The new drug, an interleukin 15 superagonist complex (ALT-803), combined ...

Recommended for you

DNA vaccine leads to immune responses in HPV-related head and neck cancer

September 21, 2018
A therapeutic vaccine can boost antibodies and T cells, helping them infiltrate tumors and fight off human papillomavirus (HPV)-related head and neck cancer. Researchers from the Abramson Cancer Center of the University of ...

In zebrafish, a way to find new cancer therapies, targeting tumor modulators

September 21, 2018
The lab of Leonard Zon, MD, at Boston Children's Hospital has long been interested in making blood stem cells in quantity for therapeutic purposes. Looking for a way to test for their presence in zebrafish, their go-to research ...

What can salad dressing tell us about cancer? Think oil and vinegar

September 20, 2018
Researchers led by St. Jude Children's Research Hospital scientists have identified another way the process that causes oil to form droplets in water may contribute to solid tumors, such as prostate and breast cancer. The ...

Novel biomarker found in ovarian cancer patients can predict response to therapy

September 20, 2018
Despite months of aggressive treatment involving surgery and chemotherapy, about 85 percent of women with high-grade wide-spread ovarian cancer will have a recurrence of their disease. This leads to further treatment, but ...

Testing fluorescent tracers used to help surgeons determine edges of breast cancer tumors

September 20, 2018
A team of researchers with members from institutions in The Netherlands and China has conducted a test of fluorescent tracers meant to aid surgeons performing tumor removal in breast cancer patients. In their paper published ...

Cancer immunotherapy might benefit from previously overlooked immune players

September 20, 2018
Cancer immunotherapy—efforts to boost a patient's own immune system, allowing it to better fight cancer cells on its own—has shown great promise for some previously intractable cancers. Yet immunotherapy doesn't work ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.